Health & Science
Tau-Targeting Alzheimer's Drug Shows Promise in Trial
Biogen's diranersen targeting tau protein shows cognitive benefits in Phase 2 Alzheimer's trial, offering a new pathway beyond amyloid.
—4 min read
Tag
4 articles
Biogen's diranersen targeting tau protein shows cognitive benefits in Phase 2 Alzheimer's trial, offering a new pathway beyond amyloid.
Dementia cases in Belgium are projected to rise 65% by 2050. A new report reveals four crucial factors determining life expectancy after diagnosis.
Belgian Alzheimer's cases projected to rise 65% by 2050, from 214,736 to 353,357. Stop Alzheimer report highlights aging and prevention potential.
A new study reveals how the APOE2 longevity gene protects neurons from aging and Alzheimer's by boosting DNA repair and resisting cellular senescence.